entertainment -WSS

entertainment

author：hotspot 2025-10-01 23:07:53 - browse：5118

What happens when an approved drug doesn’t work? Why don’t patients want gene therapy? And is MASH still a big deal?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Bioethicist Holly Fernandez Lynch joins us to discuss the case of Amylyx Pharmaceuticals’ treatment for ALS and what its failure means for drug development. We also discuss the latest news in the life sciences, including a tepid reception for gene therapies, the future of CAR-T cancer treatment, and the first approved medicine for a prevalent liver disease.

For more on what we cover, here’s more on Amylyx; here’s the story on hemophilia gene therapy; here’s the news on Madrigal Pharmaceuticals’ drug for MASH; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： How digital therapeutics firms are pivoting after Pear's bankruptcy

knowledge

WSS

Doulas covered by Medicaid under New York's new plan

How I ended up pumping milk in a bathroom stall at JPM 2024

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Doulas covered by Medicaid under New York's new plan

knowledge

entertainment

hotspot

Activists slam private health insurers over coverage restrictions

FDA clears AI tool for detecting skin cancer

Activists slam private health insurers over coverage restrictions

DeSantis can now import cheaper drugs. But will Biden get credit?

Apple is now the first public company to be valued at $3 trillion

Risky weight loss products often used by teens globally, per study

ChatGPT in medicine: STAT answers readers' burning questions

Humana cuts profit projections as Medicare Advantage costs soar

Drug repurposing or repositioning? The language matters

How digital therapeutics firms are pivoting after Pear's bankruptcy

explore

Dewpoint Therapeutics lays off staff after losing partnerships

Health and fitness trackers are measuring the wrong things

Readout LOUD podcast: live from JPM 2024

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Generative AI mines health records to identify patients’ social needs

My yearlong odyssey to get my son’s ADHD medication covered

explore

focus

knowledge

focus